Information:
Fel:
ID
41185
Beskrivning
Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00955695
Länk
https://clinicaltrials.gov/show/NCT00955695
Nyckelord
Versioner (1)
- 2020-07-07 2020-07-07 -
Rättsinnehavare
See clinicaltrials.gov
Uppladdad den
7 juli 2020
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Lung Cancer NCT00955695
Eligibility Lung Cancer NCT00955695
- StudyEvent: Eligibility
Similar models
Eligibility Lung Cancer NCT00955695
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Non-Small Cell Lung Carcinoma
Item
histologically confirmed non-small cell lung cancer
boolean
C0007131 (UMLS CUI [1])
Disease TNM clinical staging
Item
stage iiib or iv disease
boolean
C0012634 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C3258246 (UMLS CUI [1,2])
gefitinib | erlotinib hydrochloride
Item
must have had ≥ 8 weeks of gefitinib or erlotinib hydrochloride therapy
boolean
C1122962 (UMLS CUI [1])
C1533491 (UMLS CUI [2])
C1533491 (UMLS CUI [2])
Complete remission | Partial response | gefitinib | erlotinib hydrochloride
Item
at least 12 weeks of complete response or partial response since starting gefitinib or erlotinib hydrochloride
boolean
C0677874 (UMLS CUI [1])
C1521726 (UMLS CUI [2])
C1122962 (UMLS CUI [3])
C1533491 (UMLS CUI [4])
C1521726 (UMLS CUI [2])
C1122962 (UMLS CUI [3])
C1533491 (UMLS CUI [4])
Stable Disease | Criteria Quantity Fulfill
Item
stable disease allowed provided 1 of the following criteria is met:
boolean
C0677946 (UMLS CUI [1])
C0243161 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C1550543 (UMLS CUI [2,3])
C0243161 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C1550543 (UMLS CUI [2,3])
EGFR Exon 19 Mutation | EGFR Exon 21 Mutation
Item
egfr mutation (exon 19 or 21)
boolean
C4289656 (UMLS CUI [1])
C4289654 (UMLS CUI [2])
C4289654 (UMLS CUI [2])
Factor Quantity
Item
having ≥ 2 of the following 3 factors:
boolean
C1521761 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,2])
Gender
Item
female
boolean
C0079399 (UMLS CUI [1])
Never smoked tobacco
Item
never smoked
boolean
C0425293 (UMLS CUI [1])
Adenocarcinoma of lung
Item
histologically confirmed adenocarcinoma of the lung
boolean
C0152013 (UMLS CUI [1])
Metastatic malignant neoplasm to brain Absent CT scan | Metastatic malignant neoplasm to brain Absent MRI
Item
no evidence of brain metastases by ct scan or mri within the past 4 weeks
boolean
C0220650 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0040405 (UMLS CUI [1,3])
C0220650 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0024485 (UMLS CUI [2,3])
C0332197 (UMLS CUI [1,2])
C0040405 (UMLS CUI [1,3])
C0220650 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0024485 (UMLS CUI [2,3])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
ECOG performance status
Item
ecog performance status 0-2
boolean
C1520224 (UMLS CUI [1])
Absolute neutrophil count
Item
anc ≥ 1,500/mm^3
boolean
C0948762 (UMLS CUI [1])
Platelet Count measurement
Item
platelet count ≥ 150,000/mm^3
boolean
C0032181 (UMLS CUI [1])
Serum total bilirubin measurement
Item
bilirubin < 1.5 mg/dl
boolean
C1278039 (UMLS CUI [1])
Creatinine measurement, serum
Item
serum creatinine < 1.5 times upper limit of normal
boolean
C0201976 (UMLS CUI [1])
Prior Therapy
Item
prior concurrent therapy:
boolean
C1514463 (UMLS CUI [1])
ID.19
Item
see disease characteristics
boolean
Systemic Chemotherapy Quantity
Item
received 1 or 2 prior systemic chemotherapy regimens
boolean
C1883256 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,2])